In silico design and synthesis of hesperitin derivatives as new xanthine oxidase inhibitors.
Antioxidant
Hesperitin
Molecular docking
Xanthine oxidase
Journal
BMC chemistry
ISSN: 2661-801X
Titre abrégé: BMC Chem
Pays: Switzerland
ID NLM: 101741142
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
07
12
2018
accepted:
06
04
2019
entrez:
7
8
2019
pubmed:
7
8
2019
medline:
7
8
2019
Statut:
epublish
Résumé
Hesperitin, a naturally occurring flavonoid was hybridized with phenolic acids to evaluate its potential to inhibit the activity of xanthine oxidase (XO), a key enzyme which catalyses xanthine to uric acid which is found to be associated with gout and many life style related disorders. To develop new xanthine oxidase inhibitors from natural constituents along with antioxidant potential. In this report, we designed and synthesized hesperitin derivatives hybridized with natural phenolic acids to form ester linkage with the help of molecular docking. The synthesized compounds were evaluated for their antioxidant and xanthine oxidase inhibitory potential. The in vitro xanthine oxidase inhibitory activity and enzyme kinetics studies showed that hesperitin derivatives displayed a potential inhibition against XO in competitive manner with IC Taking advantage of molecular docking, this hybridization of two natural constituent could lead to desirable xanthine oxidase inhibitors with improved activity.
Sections du résumé
BACKGROUND
BACKGROUND
Hesperitin, a naturally occurring flavonoid was hybridized with phenolic acids to evaluate its potential to inhibit the activity of xanthine oxidase (XO), a key enzyme which catalyses xanthine to uric acid which is found to be associated with gout and many life style related disorders.
OBJECTIVE
OBJECTIVE
To develop new xanthine oxidase inhibitors from natural constituents along with antioxidant potential.
METHOD
METHODS
In this report, we designed and synthesized hesperitin derivatives hybridized with natural phenolic acids to form ester linkage with the help of molecular docking. The synthesized compounds were evaluated for their antioxidant and xanthine oxidase inhibitory potential.
RESULTS
RESULTS
The in vitro xanthine oxidase inhibitory activity and enzyme kinetics studies showed that hesperitin derivatives displayed a potential inhibition against XO in competitive manner with IC
CONCLUSION
CONCLUSIONS
Taking advantage of molecular docking, this hybridization of two natural constituent could lead to desirable xanthine oxidase inhibitors with improved activity.
Identifiants
pubmed: 31384801
doi: 10.1186/s13065-019-0571-1
pii: 571
pmc: PMC6661729
doi:
Types de publication
Journal Article
Langues
eng
Pagination
53Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Curr Med Chem. 2002 Jan;9(2):195-217
pubmed: 11860355
J Am Soc Nephrol. 2002 Dec;13(12):2888-97
pubmed: 12444207
J Nutr Biochem. 2002 Oct;13(10):572-584
pubmed: 12550068
Hypertension. 2003 Jun;41(6):1183-90
pubmed: 12707287
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
J Rheumatol. 2004 Aug;31(8):1582-7
pubmed: 15290739
Life Sci. 2005 Mar 4;76(16):1835-47
pubmed: 15698861
N Engl J Med. 2005 Dec 8;353(23):2450-61
pubmed: 16339094
Am J Kidney Dis. 2006 Jan;47(1):51-9
pubmed: 16377385
Arthritis Rheum. 1975 Nov-Dec;18(6 Suppl):713-9
pubmed: 173348
J Rheumatol. 2008 Sep;35(9):1859-64
pubmed: 18634142
Arthritis Res Ther. 2010;12(2):R63
pubmed: 20370912
Arthritis Rheum. 2011 Oct;63(10):3136-41
pubmed: 21800283
Pharmacognosy Res. 2010 May;2(3):152-8
pubmed: 21808558
Br J Clin Pharmacol. 2006 Dec;62(6):633-44
pubmed: 21894646
Heart. 2013 Jun;99(11):759-66
pubmed: 23343689
J Agric Food Chem. 2015 Jan 21;63(2):526-34
pubmed: 25539132
Bioorg Med Chem Lett. 2015 Aug 15;25(16):3117-9
pubmed: 26096677
J Agric Food Chem. 2015 Sep 9;63(35):7784-94
pubmed: 26285120
Int J Cardiol. 2016 Jun 15;213:8-14
pubmed: 26316329
Hypertension. 2016 Mar;67(3):496-8
pubmed: 26865197
Med Sci Monit. 2016 Jul 17;22:2501-12
pubmed: 27423335
Curr Drug Metab. 2017;18(6):577-593
pubmed: 28302027
Eur Rev Med Pharmacol Sci. 2018 Jan;22(2):506-511
pubmed: 29424910
Sci Rep. 2018 Feb 16;8(1):3137
pubmed: 29453348
Biochim Biophys Acta Mol Basis Dis. 2018 Aug;1864(8):2557-2565
pubmed: 29733945
Int J Biol Macromol. 2018 Dec;120(Pt A):1286-1293
pubmed: 30189275
Biochem Pharmacol. 1966 Jul;15(7):863-80
pubmed: 5967902
Am J Med. 1984 Jan;76(1):47-56
pubmed: 6691361
Ann Pharmacother. 1993 Mar;27(3):337-43
pubmed: 8453174
Free Radic Biol Med. 1996;20(3):331-42
pubmed: 8720903